GSK Diarrhoea Vaccine May Lose First-Mover Advantage in India

The Belgian vaccine maker GSK Biologicals’ rotaviral diarrhoea vaccine, Rotarix, is likely to miss the first-mover advantage in India. The company, which has already completed clinical studies in the country, has not yet presented the trial data to the Indian drug regulator even as two local vaccines are expected to hit the market by the year’s end.
Livemint